XTalks

MAY 26, 2023

Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical gene therapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). As a topical treatment, it is also the first readily redosable gene therapy.

Gene Therapy 97

Gene Therapy Gene FDA Approval Dermatology 97

pharmaphorum

DECEMBER 15, 2020

Eli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson’s, in a deal potentially worth more than $1 billion. The CVR pays out if one of Prevail’s gene therapies is approved in one of several developed countries before December 31, 2024.

Gene Therapy 69

Gene Therapy Gene Dermatology Trials 69

XTalks

MAY 31, 2023

In this episode, Ayesha talked about the FDA approval of the first topical gene therapy for the treatment of a rare skin condition. Krystal Biotech’s Vyjuvek is a topical gene therapy that has been approved for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB).

Gene Therapy 52

Gene Therapy Gene FDA Approval Life Science 52

pharmaphorum

OCTOBER 27, 2020

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace. . Correcting for currency fluctuations, net sales were flat at $12.3

Sales 98

Sales Gene Therapy Dermatology Gene 98

XTalks

JANUARY 2, 2024

For instance, Vyjuvek , the first FDA-approved gene therapy for DEB, is priced at $24,250 per vial. Vyjuvek is a gene therapy that employs a herpes simplex virus type 1 (HSV-1) vector. Regarding the price of Filsuvez, it has not yet been publicly disclosed by the company.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

pharmaphorum

JUNE 29, 2022

The group founded by entrepreneur Vivek Ramaswamy – which specialises in taking on surplus projects from other companies and taking the forward – is dropping six candidates, including three from its dermatology unit Dermavant.

Trials 52

Trials Dermatology Gene Therapy Drugs 52

The Pharma Data

DECEMBER 10, 2020

He became Head of Development for Rare Diseases and Gene Therapy in Sanofi-Genzyme’s office in Cambridge, Massachusetts. Dr Pirozzi subsequently was inspired to pursue a career in rare diseases after his daughter Valentina was diagnosed with a rare chromosomal syndrome, called Smith-Magenis Syndrome. positions he assumed in 2020.

Research 52

Research Doctors Doctor Medicine 52